Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (Bolero-4)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01698918
First received: October 1, 2012
Last updated: May 15, 2014
Last verified: May 2014
  Purpose

The purpose of this study is to find out if combining everolimus with letrozole is safe and has beneficial effects in postmenopausal women who have estrogen positive HER2 negative locally advanced or metastatic breast cancer. Additionally, this study aims to find out if everolimus plus exemestane is safe and has beneficial effects in women with estrogen positive locally advanced or metastatic breast cancer after treatment with everolimus plus letrozole. This study will also aim to find out if a mouth rinse can help reduce the severity of oral stomatitis, a common side effect of everolimus. This part of the study will be conducted only in countries where an alcohol free 0.5mg/5ml dexamethasone oral solution is commercially available.


Condition Intervention Phase
Hormone Receptor Positive Breast Cancer
Drug: Everolimus
Drug: Letrozole
Drug: Exemestane
Drug: Alcohol-free dexamethasone mouth rinse
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Percentage of patients progression-free after completion of 1st line treatment (everolimus + letrozole) [ Time Frame: 12 months after last patient recruited ] [ Designated as safety issue: No ]
    In this study Progression free survival is defined as the time from the date of enrollment to the date of first documented progression or death due to any cause. If a patient has not had an event, PFS will be censored at the date of the last adequate tumor assessment.


Secondary Outcome Measures:
  • Overall response rate and clinical benefit rate in patients receiving the first line study treatment (everolimus + letrozole) [ Time Frame: Baseline, every 8 weeks ] [ Designated as safety issue: No ]
    Overall response rate (ORR) is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) according to RECIST. Clinical benefit rate (CBR) is defined as the proportion of patients with best overall response of CR, PR or stable disease with a duration of 24 weeks or longer according to RECIST. ORR and CBR will be calculated based on the full analysis set, using local radiologist's/investigator's tumor assessment. Patients with only non-measurable disease at baseline will be included in the numerator if they achieve a complete response

  • Percentage of patients progression-free after completion of 2nd line treatment (everolimus + exemestane) [ Time Frame: Baseline, every 8 weeks ] [ Designated as safety issue: No ]
    In this study progression free survival in the second line is defined as the time interval between the start of the second line treatment and documented disease progression or death due to any cause reported during or after second line treatment

  • Overall survival of patients receiving first line study treatment (everolimus + letrozole) [ Time Frame: Continuous during the study and every 12 weeks after last treatment ] [ Designated as safety issue: No ]
    The overall survival (OS) following first line treatment with Everolimus + Letrozole is defined as the time from the date of receiving first line study treatment to date of death due to any cause.

  • Reduction in severity and duration of oral stomatitis [ Time Frame: Upon onset of 1st stomatitis, patient will complete diary daily until resolution of stomatitis ] [ Designated as safety issue: Yes ]
    Analysis for this objective will be based on Patient reported outcomes data for the first incidence of stomatitis AE. The mean, standard deviation and 95% confidence interval of each severity item in the questionnaire will be calculated at each day for the two therapeutic interventions for stomatitis groups and presented graphically. The duration of the first stomatitis incidence will be calculated using the dates reported in the PRO.

  • Assessment of safety based on the frequency of adverse events that fall outside normal pre-specified ranges [ Time Frame: Continuous during the study, up to 28 days after last treatment ] [ Designated as safety issue: Yes ]
    The assessment of safety will be based mainly on the frequency of adverse events and on the number of laboratory values that fall outside of pre-determined ranges. Other safety data (e.g., electrocardiogram, vital signs) will be considered as appropriate. All safety data will be listed. For all safety analyses, the safety population will be used.

  • Overall response rate and clinical benefit rate in patients receiving the second line study treatment (everolimus + exemestane) [ Time Frame: Baseline, every 8 weeks ] [ Designated as safety issue: No ]
    Overall response rate (ORR) is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) according to RECIST. Clinical benefit rate (CBR) is defined as the proportion of patients with best overall response of CR, PR or stable disease with a duration of 24 weeks or longer according to RECIST. ORR and CBR will be calculated based on the full analysis set, using local radiologist's/investigator's tumor assessment. Patients with only non-measurable disease at baseline will be included in the numerator if they achieve a complete response

  • Reduction in severity and duration of oral stomatitis [ Time Frame: Upon onset of 1st stomatitis and in countries where the alcohol-free dexamethasone solution (0.5mg/5ml) is commercially available, patient will be randomised to dexamethasone oral solution rinse or standard of care ] [ Designated as safety issue: Yes ]
    Analysis for this objective will be based on Patient reported outcomes data for the first incidence of stomatitis AE. The mean, standard deviation and 95% confidence interval of each severity item in the questionnaire will be calculated at each day for the two therapeutic interventions for stomatitis groups and presented graphically. The duration of the first stomatitis incidence will be calculated using the dates reported in the PRO.


Estimated Enrollment: 200
Study Start Date: March 2013
Estimated Study Completion Date: October 2016
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Everolimus + letrozole/exemestane
Enrolled patients will receive everolimus in combination with letrozole in the first line setting until disease progression, unacceptable toxicity or withdrawal of consent. Following disease progression in the first line setting, patients will be offered everolimus in combination with exemestane. Patients who discontinue treatment in the first line setting due to unacceptable toxicity or due to withdrawal of consent will not be offered everolimus plus exemestane. Those patients treated in the second line setting will continue treatment until disease progression, unacceptable toxicity or withdrawal of consent.
Drug: Everolimus
Everolimus will be self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously from study day 1 until progression of disease, unacceptable toxicity or withdrawal of consent. Everolimus should be taken at the same time every day. Everolimus tablets should be swallowed whole with a glass of water once daily, either consistently with food or consistently without food. Tablets should not be chewed or crushed.
Other Name: RAD001
Drug: Letrozole
1st line study treatment: Letrozole will be self administered as a daily dose of 2.5mg continuously from study day 1 until disease progression, unacceptable toxicity or withdrawal of consent and should be taken at the same time every day, consistently with or without food. Everolimus and letrozole tablets should be taken together.
Other Name: Femara
Drug: Exemestane
2nd Line Study Treatment: If patients progress on everolimus + letrozole, patients will be offered everolimus + exemestane. Exemestane will be self administered as a daily dose of 25mg taken orally continuously until disease progression, unacceptable toxicity or withdrawal of consent and should be taken at the same time every day after a meal. Everolimus and exemestane tablets should be taken together.
Other Name: Aromasin
Drug: Alcohol-free dexamethasone mouth rinse
At the onset of symptoms suggestive of stomatitis patients must contact the study site. Upon confirmation of stomatitis at the site, patients in countries where the alcohol-free 0.5mg/5ml dexamethasone oral solution is commercially available will be randomly assigned to take either dexamethasone 0.5 mg/5ml mouth rinse or the standard of care used to treat stomatitis at the patient's center. The mouth rinse will be self administered at a daily dose of 10ml 3 times per day. Patients will be instructed to swish and expectorate the mouth rinse. Patients will also be instructed to fill out the Oral Stomatitis Daily Questionnaire (OSDQ) at home every day until the patient recovers. The mouth rinse will be self administered at a daily dose of 10ml 3 times per day.Patients will be instructed to swish and expectorate the mouth rinse.
Other Name: alcohol-free dexamethasone 0.5 mg/5ml

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients 18 years old or greater
  • Patients with metastatic or locally advanced, unresectable breast cancer not amenable to curative treatment by surgery or radiotherapy
  • Histological or cytological confirmation of estrogen-receptor positive (ER+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer
  • Postmenopausal women
  • No prior treatment for metastatic breast cancer

Exclusion Criteria:

  • Patients with only non-measurable lesions other than bone metastases (e.g., pleural effusion, ascites, etc)
  • Patients who have received prior hormonal or any other systemic therapy for metastatic breast cancer.
  • Patients may have received prior neoadjuvant or adjuvant endocrine therapy. In the case of neoadjuvant or adjuvant NSAI (letrozole/anastrozole) therapy patients must have completed therapy at least 1 year prior to study enrollment.
  • Previous treatment with mTOR inhibitors.
  • Known hypersensitivity to mTOR inhibitors, e.g., sirolimus (rapamycin).
  • Other protocol-defined inclusion/exclusion criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01698918

Contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682
Contact: Novartis Pharmaceuticals

  Hide Study Locations
Locations
United States, Alabama
University of Alabama Comprehensive Cancer Center SC-2 Recruiting
Birmingham, Alabama, United States, 35294
Contact: Alfreda Lewis    205-978-2848    alfreda.lewis@ccc.uab.edu   
Principal Investigator: Andres Forero-Torres         
United States, Arizona
Banner MD Anderson Cancer Center Recruiting
Gilbert, Arizona, United States, 85234
Contact: Shana Clark    *see departments*    shannon.johnson2@bannerhealth.com   
Principal Investigator: Mary Cianfrocca         
United States, California
Loma Linda University Loma Linda Recruiting
Loma Linda, California, United States, 92354
Contact: Lorena Garcia    909-558-4050    lcgarcia@llu.edu   
Principal Investigator: Yuan Yuan         
Breastlink Medical Group Dept. of BreastlinkResearchGrp Recruiting
Long Beach, California, United States, 90806
Contact: Andrea Provost    +1 562 981 6101 ext 115    Andrea.provost@breastlink.com   
Principal Investigator: John S. Link         
United States, Illinois
Northwestern University SC Not yet recruiting
Chicago, Illinois, United States, 60611
Contact: Raynette Thompkins    312-695-1387    r-thompkins@northwestern.edu   
Principal Investigator: William J. Gradishar         
Oncology Specialists, SC Dept.of Oncology Specialists Recruiting
Park Ridge, Illinois, United States, 60068-0736
Contact: Milenna Undda    847-410-0660    mundda@oncmed.net   
Principal Investigator: Sigrun Hallmeyer         
United States, Kansas
St. Francis Health Comprehensive Cancer Center Not yet recruiting
Topeka, Kansas, United States, 6606-169
Contact: Kelly Knoebber-Carr    785-270-5198      
Principal Investigator: Jameel Kyasa         
United States, Kentucky
Norton Healthcare, Inc. SC Recruiting
Louisville, Kentucky, United States, 40202
Contact: Juli Brown    502-629-5315    juli.brown@nortonhealthcare.org   
Principal Investigator: Janell Seeger         
United States, Maryland
Holy Cross Hospital Holy Cross Recruiting
Silver Spring, Maryland, United States, 20910
Contact: Shebna Garcon       garconsm@holycrosshealth.org   
Principal Investigator: Cheryl Aylesworth         
United States, Massachusetts
Baystate Medical Center SC Not yet recruiting
Springfield, Massachusetts, United States, 00119
Contact: Katherine Colbeck    413-794-9875    Katherine.colbeck@baystatehealth.org   
Principal Investigator: James Stewart         
United States, Missouri
Mercy Medical Research Institute SC Recruiting
Manchester, Missouri, United States, 63021
Contact: Pearlena Hamlet    417-820-8099    pearlena.hamlet@mercy.net   
Principal Investigator: Viran R. Holden         
United States, Nebraska
Nebraska Methodist Hospital SC-1 Recruiting
Omaha, Nebraska, United States, 68114
Contact: Ann Burch       ann.burch@alegent.org   
Principal Investigator: Margaret Barbara Block         
United States, New Jersey
Saint Barnabas Medical Center CancerCenter of Saint Barnabas Recruiting
Livingston, New Jersey, United States, 07039
Contact: Kathy Bryckta    973-322-2470    kbrychta@barnabashealth.org   
Principal Investigator: Richard A. Michaelson         
United States, New Mexico
University of New Mexico Hospital SC Recruiting
Albuquerque, New Mexico, United States, 87106
Contact: Emily Lytle    505-925-0416    Emily.lytle@nmcancercare.com   
Principal Investigator: Melanie Royce         
United States, New York
Broome Oncology SC Not yet recruiting
Johnson City, New York, United States, 13790
Contact: Carolyn Grausgruber    607-763-8065    cgrausgruber@broomeoncology.com   
Principal Investigator: Ronald Harris         
Columbia University Medical Center- New York Presbyterian Columbia Recruiting
New York, New York, United States, 10032
Contact: Lois Brafman    212-304-5579    mk3007@columbia.edu   
Principal Investigator: Matthew A. Maurer         
United States, North Carolina
Cone Health Cancer Center Recruiting
Greensboro, North Carolina, United States
Contact: Chantay Witcher    +1 336 832 0836    chantay.witcher@conehealth.com   
Principal Investigator: James Mitchell Granfortuna         
Marion L. Shepard Cancer Center SC Not yet recruiting
Washington, North Carolina, United States, 27889
Contact: Nichole Manning       nichole.manning@vidanthealth.com   
Principal Investigator: John J. Inzerillo         
United States, Pennsylvania
Geisinger Health System GHS Withdrawn
Danville, Pennsylvania, United States, 17822-2170
United States, Texas
Texas Oncology, P.A. Dallas Presbyterian Not yet recruiting
Dallas, Texas, United States, 75251
Principal Investigator: Kristi J. McIntyre         
Texas Oncology Central Monitoring Not yet recruiting
Dallas, Texas, United States, 75251
Principal Investigator: Texas Oncology         
Texas Oncology, P.A. Dallas Methodist Not yet recruiting
Dallas, Texas, United States, 75251
Principal Investigator: John V. Cox         
Texas Oncology, P.A. Harlingen Not yet recruiting
Dallas, Texas, United States, 75251
Principal Investigator: Nabeel Sarhill         
Texas Oncology, P.A. Paris Not yet recruiting
Dallas, Texas, United States, 75251
Principal Investigator: Sucharu Prakash         
Texas Oncology, P.A. Sherman Not yet recruiting
Dallas, Texas, United States, 75251
Principal Investigator: Tammy E. Roque         
Texas Oncology, P.A. Waco Not yet recruiting
Dallas, Texas, United States, 75251
Principal Investigator: Carlos A. Encarnacion         
East Texas Hematology Clinic SC Recruiting
Lufkin, Texas, United States, 75904
Contact: Kavitha Pinnamaneni       kavithapinnamaneni@yahoo.com   
Principal Investigator: Kavitha Pinnamaneni         
United States, Utah
Utah Cancer Specialists Dept.of Utah Cancer Spec. (3) Recruiting
Salt Lake City, Utah, United States, 84106
Contact: Bianca McGraw    801-281-6864    bmcgraw@utahcancer.com   
Principal Investigator: W. Graydon Harker         
United States, Virginia
Lynchburg Hematology & Oncology Clinic SC Withdrawn
Lynchburg, Virginia, United States, 24501
Argentina
Novartis Investigative Site Not yet recruiting
Caba, Buenos Aires, Argentina, C1181ACH
Novartis Investigative Site Not yet recruiting
Santa Rosa, La Pampa, Argentina, 6300
Novartis Investigative Site Not yet recruiting
Posadas, Misiones, Argentina, 3300
Novartis Investigative Site Withdrawn
Rosario, Santa Fe, Argentina, S2000KZE
Austria
Novartis Investigative Site Withdrawn
Leoben, Austria, A-8700
Novartis Investigative Site Withdrawn
Linz, Austria, 4010
Novartis Investigative Site Withdrawn
Wels, Austria, A-4600
Brazil
Novartis Investigative Site Withdrawn
Brasilia, DF, Brazil, 70330-150
Novartis Investigative Site Not yet recruiting
Porto Alegre, RS, Brazil, 90560-030
Novartis Investigative Site Not yet recruiting
Porto Alegre, RS, Brazil, 90035-903
Novartis Investigative Site Not yet recruiting
São Paulo, SP, Brazil, 03102-002
Novartis Investigative Site Not yet recruiting
São Paulo, SP, Brazil, 01317-002
France
Novartis Investigative Site Recruiting
Besançon cedex, France, 25030
Novartis Investigative Site Recruiting
Bordeaux, France, 33076
Novartis Investigative Site Recruiting
Brest, France, 29200
Novartis Investigative Site Not yet recruiting
Hyères, France, 83400
Novartis Investigative Site Recruiting
Le Chesnay, France, 78157
Novartis Investigative Site Recruiting
Lyon Cedex, France, 69373
Novartis Investigative Site Recruiting
Nancy, France, 54000
Novartis Investigative Site Recruiting
Nantes cedex 2, France, 44202
Hungary
Novartis Investigative Site Withdrawn
Debrecen, Hungary, 4032
Novartis Investigative Site Withdrawn
Gyor, Hungary, 9000
Novartis Investigative Site Recruiting
Gyula, Hungary, 5703
Novartis Investigative Site Not yet recruiting
Kaposvar, Hungary, 7400
Novartis Investigative Site Not yet recruiting
Kecskemet, Hungary, 6000
Novartis Investigative Site Not yet recruiting
Kistarcsa, Hungary, 2143
Novartis Investigative Site Withdrawn
Szeged, Hungary, 6720
Novartis Investigative Site Not yet recruiting
Szekszard, Hungary, 7100
Japan
Novartis Investigative Site Recruiting
Nagoya-city, Aichi, Japan, 467-8602
Novartis Investigative Site Recruiting
Sapporo, Hokkaido, Japan
Novartis Investigative Site Recruiting
Morioka-city, Iwate, Japan, 020-8505
Novartis Investigative Site Recruiting
Kawasaki-city, Kanagawa, Japan, 216-8511
Novartis Investigative Site Recruiting
Kumamoto City, Kumamoto, Japan, 860-8556
Korea, Republic of
Novartis Investigative Site Recruiting
Seoul, Korea, Korea, Republic of, 135-710
Novartis Investigative Site Recruiting
Seoul, Korea, Republic of, 139-706
Novartis Investigative Site Recruiting
Seoul, Korea, Republic of, 135-720
Netherlands
Novartis Investigative Site Recruiting
Maastricht, Netherlands, 5800
Portugal
Novartis Investigative Site Not yet recruiting
Lisboa, Portugal, 1649-035
Novartis Investigative Site Recruiting
Lisboa, Portugal, 1400-038
Spain
Novartis Investigative Site Recruiting
Sabadell, Barcelona, Spain, 08208
Novartis Investigative Site Recruiting
Salamanca, Castilla y Leon, Spain, 37007
Novartis Investigative Site Recruiting
Valencia, Comunidad Valenciana, Spain, 46010
Novartis Investigative Site Recruiting
La Coruna, Galicia, Spain, 15006
Thailand
Novartis Investigative Site Recruiting
Bangkok, Thailand, 10330
Novartis Investigative Site Recruiting
Bangkok, Thailand, 10400
Novartis Investigative Site Recruiting
Bangkok, Thailand, 10700
Turkey
Novartis Investigative Site Recruiting
Altunizade, Turkey, 34662
Novartis Investigative Site Recruiting
Antalya, Turkey, 07059
Novartis Investigative Site Recruiting
Istanbul, Turkey, 34303
Novartis Investigative Site Recruiting
Izmir, Turkey, 35040
United Kingdom
Novartis Investigative Site Recruiting
Bath, United Kingdom, BA1 3NG
Novartis Investigative Site Withdrawn
Glasgow, United Kingdom, G42 9TY
Novartis Investigative Site Recruiting
Norwich, United Kingdom, NR1 3SR
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01698918     History of Changes
Other Study ID Numbers: CRAD001Y24135, 2012-003065-17
Study First Received: October 1, 2012
Last Updated: May 15, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
metastatic breast cancer, locally advanced breast cancer, HER2-, ER+, everolimus, Afinitor

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Ethanol
Sirolimus
Dexamethasone
Dexamethasone acetate
Dexamethasone 21-phosphate
Exemestane
Letrozole
BB 1101
Everolimus
Anti-Infective Agents, Local
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Central Nervous System Depressants
Physiological Effects of Drugs
Central Nervous System Agents
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal

ClinicalTrials.gov processed this record on July 20, 2014